期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

规范我国Ph染色体阴性骨髓增殖性肿瘤的临床诊治

Standardization of Diagnosis and Treatment of Philadelphia Chromsome Negtive Myeloproliferative Neoplasms
原文传递
导出
摘要 JAK2 V617F等基因突变的发现使骨髓增殖性疾病的概念演变成了骨髓增殖性肿瘤（MPN）.同时MPN的诊断分型也进入了半分子学时代,各种预后分组模式的相继提出和完善,格列卫在PDGFR-α和PDGFRβ受累MPN治疗中的成功应用,以及JAK2抑制剂的问世有望进一步改善患者的生存.
作者 肖志坚
机构地区 中国医学科学院北京协和医学院血液病医院
出处 《国际输血及血液学杂志》 CAS 2011年第3期193-194,共2页 International Journal of Blood Transfusion and Hematology
基金 课题资助：卫生行业科研专项（No.201002024）
关键词 骨髓增殖性疾病 PH染色体 临床诊治 肿瘤 PDGFR-Α 阴性 PDGFRβ JAK2
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1Swerdlow SH,Campo E,Harris NL,et al.WHO classification of tumours of haematopoietic and lymphoid tissues.4th.Lyon,France:IARC Press,2008:31-64.
  • 2Tefferi A,Vardiman JW.Classification and diagnosis of myeloproliferative neoplasms:The 2008 World Health Organization criteria and point-of-care diagnostic algorithms.Leukemia,2008,22(1):14-22.
  • 3肖志坚.规范和重视原发性骨髓纤维化的诊断和治疗[J].白血病．淋巴瘤,2010,19(9):513-516. 被引量：13
  • 4肖志坚.骨髓增生异常综合征和骨髓增殖性肿瘤的诊断分型应重视的一些问题[J].中华血液学杂志,2010,31(4):217-218. 被引量：11
  • 5Barbui T,Barosi G,Birgegard G,,et al.Philadelphia-Negative classical myeloproliferative neoplasms:critical concepts and management recommendations from European Leukemia Net.J Clin Oncol,2011,29(6),761-770.
  • 6Baccarani M,Cilloni D,Rondoni M,et al.The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRa positive hypereosinophilic syndrome.Results of a multicenter prospective study.Haematologica,2007,92(9),1173-1179.

二级参考文献19

  • 1Kr(o)ger N,Holler E,Kobbe G,et al.Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis:a prospective,multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Blood,2009,114:5264-5270.
  • 2Zang DY,Deeg HJ.Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.Curr Opin Hematol,2009,16:140-146.
  • 3Thomas DA,Giles FJ,Albitar M,et al.Thalidomide therapy for myelofibrosis with myeloid metaplasia.Cancer,2006,106:1974-1984.
  • 4Abgrall JF,Guibaud I,Bastie JN,et al.Thalidomide versus placebo in myeloid metaplasia with myelofibrosis:a prospective,randomized,double-blind,multicenter study.Haematologica,2006,91:1027-1032.
  • 5Tefferi A,Cortes J,Verstovsek S,et al.Lenalidomide therapy in myelofibrosis with myeloid metaplasia.Blood,2006,108:1158-1164.
  • 6Quint ás-Cardama A,Kantarjian HM,Manshouri T,et al.Lenalidomide plus prednisone results in durable clinical,histopathologic,and molecular responses in patients with myelofibrosis.J Clin Oncol,2009,27:4760-4766.
  • 7Chee L,Kalnins R,Turner P.Low dose melphalan in the treatment of myelofibrosis:a single centre experience.Leuk Lymphoma,2006,47:1409-1412.
  • 8Mishchenko E,Tefferi A.Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms:JAK2inhibitors,radiotherapy,splenectomy and transjugular intrahepatic portosystemic shunt.Eur J Haematol,2010,Jun 2.[Epub ahead of print].
  • 9Tefferi A,Verstovsek S,Barosi G,et al.Pomalidomide is active in the treatment of anemia associated with myelofibrosis.J Clin Oncol,2009,27:4563-4569.
  • 10Barosi G,Bordessoule D,Briere J,et al.Response criteria for myelofibrosis with myeloid metaplasia:results of an initiative of the European Myelofibrosis Network (EUMNET).Blood,2005,106:2849-2853.

共引文献21

国际输血及血液学杂志
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部